EP1802294A1 - Composes carbamate destines au traitement de pathologies neurodegeneratives - Google Patents

Composes carbamate destines au traitement de pathologies neurodegeneratives

Info

Publication number
EP1802294A1
EP1802294A1 EP05810159A EP05810159A EP1802294A1 EP 1802294 A1 EP1802294 A1 EP 1802294A1 EP 05810159 A EP05810159 A EP 05810159A EP 05810159 A EP05810159 A EP 05810159A EP 1802294 A1 EP1802294 A1 EP 1802294A1
Authority
EP
European Patent Office
Prior art keywords
formula
group
day
enantiomer
rats
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05810159A
Other languages
German (de)
English (en)
Inventor
Roy E. Twyman
Boyu Zhao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of EP1802294A1 publication Critical patent/EP1802294A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • the present invention relates generally to the fields of pharmacology, neurology and psychiatry and to methods of protecting the cells of a mammalian central nervous system from damage or injury. More specifically, this invention provides methods for the use of certain carbamate compounds for neuroprotection.
  • CNS central nervous system
  • PNS peripheral nervous system
  • Neuronal degeneration as a result of, for example; Alzheimer's disease, multiple sclerosis, cerebral-vascular accidents (CVAs) stroke, traumatic brain injury, spinal cord injuries, degeneration of the optic nerve, e.g., ischemic optic neuropathy or retinal degeneration and other central nervous system disorders is an enormous medical and public health problem by virtue of both its high incidence and the frequency of long- term sequelae.
  • Animal studies and clinical trials have shown that amino acid transmitters (especially glutamate), oxidative stress and inflammatory reactions contribute strongly to cell death in these conditions.
  • Glutamate is a negatively charged amino acid that is an excitatory synaptic transmitter in the mammalian nervous system.
  • glutamate can reach the millimolar range in nerve terminals its extracellular concentration is maintained at a low level to prevent neurotoxicity. It has been noted that glutamate can be toxic to neurons if presented at a high concentration.
  • excitotoxicity has been used to describe the cytotoxic effect that glutamate (and other such excitatory amino acids) can have on neurons when applied at high dosages.
  • Such therapies include glutamate release inhibitors, glutamate receptor antagonists, Ca2+ channel blockers, GABA receptor agonists, gangliosides, neurotrophic factors, calpain inhibitors, caspase inhibitors, free radical scavengers, immuno- and cell metabolism modulators.
  • AD Alzheimer's disease
  • ALS Amyotropic Lateral Sclerosis
  • Parkinsonian dementia of Guam (Caine et al, (1986), Lancet 2: 1067-1070) as well as in the neuropathology associated with stroke, ischemia and reperfusion (See, Dykens et al, (1987), J.
  • NMDA N-methyl-D-aspartate
  • AD Alzheimer's disease
  • APP amyloid precursor protein
  • Parkinson's disease is a progressive neurodegenerative disorder characterized by a dysfunction of movement consisting of akinesia, rigidity, tremor and postural abnormalities. This disease has been associated with the loss of nigro-striatal dopaminergic neuronal integrity and functionality as evidenced by substantial loss of dopaminergic neurons in substantia nigra pars compacta (SNpc) (See, Pakkenberg et al. (1991) J. Neurol. Neurosurg. Psychiat. 54:30-33), and a decrease in content, synaptic and vesicular transporters of dopamine in the striatum (see, for example, Guttnan et al. (1997j Neurology 48: 1578-1583).
  • PNS nervous system of mammals including humans as a result of trauma, injury of many kinds, ischemia, metabolic derangements, e.g., diabetes hypoxia, toxins or surgical intervention causes both acute and chronic and progressive loss of function and disability.
  • the present invention relates in general to neuroprotective methods, and more specifically to methods and compounds for prevention of damage to cells of the mammalian central and peripheral nervous system resulting from injury, trauma, surgery or acute or chronic disease processes.
  • This invention is based, in part, on the discovery that the administration of one or more members of a family of carbamate compounds either alone or in combination with one or more other neuroprotective medications provides a neuroprotective effect on the mammalian nervous system.
  • Neuroprotection provided by this invention includes protection from damage resulting from neural injury or insult and from neurotoxicity, including excitotoxicity.
  • neuroprotection provided by this invention will be useful in the treatment of acute and chronic neurodegenerative disorders that may involve excitotoxicity, for example glutamate excitotoxicity, including stroke/ischemia, surgical trauma, Traumatic Brain Injury (TBI), blunt, closed or penetrating head trauma, epilepsy, Huntington's disease, Amyotrophic Lateral Sclerosis (ALS), diabetic neuropathy and hypoglycemic encephalopathy.
  • excitotoxicity for example glutamate excitotoxicity, including stroke/ischemia, surgical trauma, Traumatic Brain Injury (TBI), blunt, closed or penetrating head trauma, epilepsy, Huntington's disease, Amyotrophic Lateral Sclerosis (ALS), diabetic neuropathy and hypoglycemic encephalopathy.
  • Neuroprotection provided by this invention may be brought about upon injured or diseased tissue or in a preventative fashion during or prior to events expected to lead to a neural insult.
  • the invention provides methods for providing neuroprotection; for inhibiting cell degeneration or cell death; for treatment or prophylaxis of a neurodegenerative disease; or for ameliorating the cytotoxic effect of a compound (for example, a excitatory amino acid such as glutamate; a toxin; or a prophylactic or therapeutic compound that exerts a cytotoxic side effect) in a subject in need thereof, by administering to the subject an effective amount of a compound of the invention, or it's pharmaceutically acceptable salt or ester either alone or in combination with another medication along with a pharmaceutically acceptable excipient.
  • the methods of the invention include protection against excitotoxicity, for example glutamate excitotoxicity.
  • the subject for example, a human, may be suffering from neural insult or injury; or may be suffering from a condition selected from substance abuse, trauma, stroke, ischemia, Huntington's disease, Alzheimer's disease, Parkinson's disease, prion disease, variant Creutzfeld-Jakob disease, amyotrophic or hypoglycemic encephalopathy; or may be undergoing surgery or other intervention.
  • the subject may have a pre ⁇ existing condition that would benefit by neuroprotection or the patient may be treated to reduce deleterious effects of a concomitant or subsequent neural injury, such as may occur during surgery or other intervention.
  • the present invention provides methods for providing neuroprotection comprising administering to a subject in need thereof a therapeutically effective amount of a composition that comprises at least one compound having Formula 1 or Formula 2:
  • Ci-C 4 alkyl group of Formula 1 or Formula 2 can be substituted or unsubstituted.
  • the CrC 4 alkyl group is substituted with a phenyl group.
  • the phenyl group can be unsubstituted or substituted.
  • the phenyl group is unsubstituted or substituted with halogen, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, amino, nitro, or cyano.
  • X 1 , X 2 , X3, X4, and X 5 can be hydrogen, fluorine, chlorine, bromine or iodine.
  • X 1 , X 2 , X 3 , X 4 , and X 5 are, independently, hydrogen or chlorine.
  • X-i is fluorine, chlorine, bromine or iodine.
  • X 1 is chlorine and X 2 , X 3 , X 4 , and X 5 are, independently, hydrogen.
  • R 1 , R 2 , R3, and R 4 are, independently, hydrogen.
  • the present invention provides enantiomers of Formula 1 or Formula 2 for providing neuroprotection in a subject.
  • a compound of Formula 1 or Formula 2 will be in the form of a single enantiomer thereof.
  • a compound of Formula 1 or Formula 2 will be in the form of an enantiomeric mixture in which one enantiomer predominates with respect to another enantiomer.
  • the enantiomer will predominate to the extent of 90% or greater or to the extent of 98% or greater.
  • the present invention also provides methods comprising administering to a subject a neuroprotective amount of a composition that comprises at least one compound having Formula 1 or Formula 2 wherein R 1 , R 2 , R 3 , and R 4 are, independently, hydrogen or C 1 -C 4 alkyl; and X 1 , X 2 , X 3 , X 4 , and X 5 are, independently, hydrogen, fluorine, chlorine, bromine or iodine.
  • a determination will be made as to whether or not the subject suffers from some form of acute or chronic neurodegeneration or nervous system injury.
  • the present invention also provides methods comprising identifying a patient at risk of developing acute or chronic neurodegeneration or nervous system injury or a patient in need of treatment with a neuroprotective drug (NPD), as defined below and administering a composition that comprises at least one compound having Formula 1 or Formula 2 to the subject.
  • NPD neuroprotective drug
  • a therapeutically effective amount of a compound having Formula 1 or Formula 2 for providing neuroprotection is from about 1.0 mg/Kg/dose to about 150 mg/Kg/dose. In a 70 kg human this would correspond to a daily dose of from about 70 mg/day to about 10,500 mg/day. 2005/036695
  • a therapeutically effective amount of pharmaceutical composition for providing neuroprotection comprising one or more of the enantiomers of this invention or a pharmaceutically acceptable salt or ester thereof and a pharmaceutically acceptable carrier or excipient is administered to a subject or patient in need of treatment with a neuroprotective drug or NPD.
  • compositions comprising at least one compound having Formula 1 or Formula 2 are administered to subjects in need thereof.
  • a subject or patient in need of treatment with a neuroprotective drug or NPD may be one who has experienced some form of acute trauma or injury to the cells of the central or peripheral nervous or who has some form of acute or chronic neurodegenerative disorder.
  • the subject or patient will be determined to be at risk for developing an acute or chronic neurodegenerative disorder at the time of administration, i.e., a patient in need of treatment with a neuroprotective drug.
  • a subject in need thereof is one who has acute injury or trauma to the cells of their nervous system at the time of administration.
  • Figure 1 is a graph that shows the effects of increasing doses of TC on the number of neurons in different areas of the hippocampus counted at 14 days after li-pilo SE. Values are expressed as the number of neuronal cell bodies in each area of interest ⁇ S. E. M.
  • Figure 2 is a graph that shows the effects of increasing doses of TC on the number of neurons in different nuclei of the amygdala counted at 14 days after li-pilo SE. Values are expressed as the number of neuronal cell bodies in each area of interest ⁇ S.E.M.
  • Figure 3 is a graph that shows the effects of increasing doses of TC on the number of neurons in different nuclei of the thalamus counted at 14 days after li-pilo SE. Values are expressed as the number of neuronal cell bodies in each area of interest ⁇ S. E. M.
  • Figure 4 is a graph that shows the effects of increasing doses of TC on the number of neurons in different areas of the cortex counted at 14 days after li- pilo SE. Values are expressed as the number of neuronal cell bodies in each area of interest ⁇ S.E.M.
  • Figure 5 is a graph that shows the effects of increasing doses of TC on the latency to the first spontaneous seizure. Values are expressed as the mean latency in days for each group ⁇ S.E.M.
  • Figure 8 shows the correlation between the latency to the first spontaneous seizure and the total number of seizures observed during the four following weeks.
  • the present invention provides methods of using certain 2-phenyl-1 ,2- ethanediol monocarbomates and dicarbamates to provide neuroprotection to mammals in need thereof.
  • Suitable methods for synthesizing and purifying carbamate compounds, including carbamate enantiomers, used in the methods of the present invention are well known to those skilled in the art.
  • pure enantiomeric forms and enantiomeric mixtures of 2-phenyl-1 , 2-ethanediol monocarbomates and dicarbamates are described in United States Patent Numbers 5,854,283, 5,698,588, and 6,103,759, the disclosures of which are herein incorporated by reference in their entirety.
  • Representative carbamate compounds according to the present invention include those having Formula 1 or Formula 2:
  • R 1 , R 2 , R 3 , and R 4 are, independently, hydrogen or C 1 -C 4 alkyl and X-i, X 2 , X3, X 4 , and X 5 are, independently, hydrogen, fluorine, chlorine, bromine or iodine.
  • CyC 4 alkyl refers to substituted or unsubstituted aliphatic hydrocarbons having from 1 to 4 carbon atoms. Specifically included within the definition of "alkyl” are those aliphatic hydrocarbons that are optionally substituted. In a preferred embodiment of the present invention, the C 1 -C 4 alkyl is either unsubstituted or substituted with phenyl.
  • phenyl as used herein, whether used alone or as part of another group, is defined as a substituted or unsubstituted aromatic hydrocarbon ring group having 6 carbon atoms. Specifically included within the definition of “phenyl” are those phenyl groups that are optionally substituted. For example, in a preferred embodiment of the present invention, the, "phenyl” group is either unsubstituted or substituted with halogen, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, amino, nitro, or cyano.
  • X 1 is fluorine, chlorine, bromine or iodine and X 2 , X 3 , X 4 , and X 5 are hydrogen.
  • X 1 , X 2 , X 3 , X 4 , and X 5 are, independently, chlorine or hydrogen.
  • R 1 , R 2 , R 3 , and R 4 are all hydrogen.
  • substituents and substitution patterns on the compounds of the present invention can be selected by one of ordinary skill in the art to provide compounds that are chemically stable and that can be readily synthesized by techniques known in the art as well as the methods provided herein.
  • 2-phenyl-1 , 2-ethanediol monocarbomates and dicarbamates include, for example, the following compounds: T7US2005/036695
  • the present invention includes the use of isolated enantiomers of
  • a pharmaceutical composition comprising the isolated S-enantiomer of Formula 1 is used to provide neuroprotection in a subject.
  • a 005/036695 is used to provide neuroprotection in a subject.
  • composition comprising the isolated R-enantiomer of Formula 2 is used to provide neuroprotection in a subject.
  • a pharmaceutical composition comprising the isolated S-enantiomer of Formula 1 and the isolated R-enantiomer of Formula 2 can be used to provide neuroprotection in a subject.
  • the present invention also includes the use of mixtures of enantiomers of Formula 1 or Formula 2.
  • one enantiomer will predominate.
  • An enantiomer that predominates in the mixture is one that is present in the mixture in an amount greater than any of the other enantiomers present in the mixture, e.g., in an amount greater than 50%.
  • one enantiomer will predominate to the extent of 90% or to the extent of 91%, 92%, 93%, 94%, 95%, 96%, 97% or 98% or greater.
  • the enantiomer that predominates in a composition comprising a compound of Formula 1 is the S-enantiomer of Formula 1.
  • the enantiomer that predominates in a composition comprising a compound of Formula 2 is the R-enantiomer of Formula 2.
  • the enantiomer that is present as the sole enantiomer or as the predominate enantiomer in a composition of the present invention is represented by Formula 3 or Formula 5, wherein X 1 , X 2 , X3, X4, X5, R-i, R2, R3 > and R 4 are defined as above, or by Formula 7 or Formula 8.
  • the present invention provides methods of using enantiomers and enantiomeric mixtures of compounds represented by Formula 1 and Formula
  • a carbamate enantiomer of Formula 1 or Formula 2 contains an asymmetric chiral carbon at the benzylic position, which is the aliphatic carbon adjacent to the phenyl ring.
  • an enantiomer that is isolated is one that is substantially free of the corresponding enantiomer.
  • an isolated enantiomer refers to a compound that is separated via separation techniques or prepared free of the corresponding enantiomer.
  • substantially free means that the compound is made up of a significantly greater proportion of one enantiomer.
  • the compound includes at least about 90% by weight of a preferred enantiomer. In other embodiments of the invention, the compound includes at least about 99% by weight of a preferred enantiomer.
  • Preferred enantiomers can be isolated from racemic mixtures by any method known to those skilled in the art, including high performance liquid chromatography (HPLC) and the formation and crystallization of chiral salts, or preferred enantiomers can be prepared by methods described herein.
  • HPLC high performance liquid chromatography
  • compounds of the present invention can be prepared as described in United States Patent Number 3,265,728 (the disclosure of which is herein incorporated by reference in its entirety and for all purposes), 3,313,692 (the disclosure of which is herein incorporated by reference in its entirety and for all purposes), and the previously referenced United States Patent Numbers 5,854,283, 5,698,588, and 6,103,759 (the disclosures of which are herein incorporated by reference in their entirety and for all purposes).
  • This nervous system injury may take the form of an abrupt insult or an acute injury to the nervous system as in, for example, acute neurodegenerative disorders including, but not limited to; acute injury, hypoxia- ischemia or the combination thereof resulting in neuronal cell death or compromise.
  • Acute injury includes, but is not limited to, Traumatic Brain Injury (TBI) including, closed, blunt or penetrating brain trauma, focal brain trauma, diffuse brain damage, spinal cord injury, intracranial or intravertebral lesions (including, but not limited to, contusion, penetration, shear, compression or laceration lesions of the spinal cord or whiplash shaken infant syndrome.
  • TBI Traumatic Brain Injury
  • deprivation of oxygen or blood supply in general can cause acute injury as in hypoxia and/or ischemia including, but is not limited to, cerebrovascular insufficiency, cerebral ischemia or cerebral infarction (including cerebral ischemia or infarctions originating from embolic occlusion and thrombosis, retinal ischemia (diabetic or otherwise), glaucoma, retinal degeneration, multiple sclerosis, toxic and ischemic optic neuropathy, reperfusion following acute ischemia, perinatal hypoxic-ischemic injury, cardiac arrest or intracranial hemorrhage of any type (including, but not limited to, epidural, subdural, subarachnoid or intracerebral hemorrhage).
  • Trauma or injury to tissues of the nervous system may also take the form of more chronic and progressive neurodegenerative disorders, such as those associated with progressive neuronal cell death or compromise over a period of time including, but not limited to, Alzheimer's disease, Pick's disease, diffuse Lewy body disease, progressive supranuclear palsy (Steel-Richardson syndrome), multisystem degeneration (Shy-Drager syndrome), chronic epileptic conditions associated with neurodegeneration, motor neuron diseases (amyotrophic lateral sclerosis), multiple sclerosis, degenerative ataxias, cortical basal degeneration, ALS-Parkinson's-Dementia complex of Guam, subacute sclerosing panencephalitis, Huntington's disease, Parkinson's disease, synucleinopathies (including multiple system atrophy), primary progressive aphasia, striatonigral degeneration, Machado-Joseph disease or 5 036695
  • spinocerebellar ataxia type 3 and olivopontocerebellar degenerations bulbar and pseudobulbar palsy, spinal and spinobulbar muscular atrophy (Kennedy's disease), primary lateral sclerosis, familial spastic paraplegia, Werdnig- Hoffmann disease, Kugelberg-Welander disease, Tay-Sach's disease, Sandhoff disease, familial spastic disease, Wohlfart-Kugelberg-Welander disease, spastic paraparesis, progressive multifocal leukoencephalopathy, familial dysautonomia (Riley-Day syndrome) or prion diseases (including, but not limited to Creutzfeld-Jakob disease, Gerstmann-Strussler-Scheinker disease, Kuru disease or fatal familial insomnia).
  • trauma and progressive injury to the nervous system can take place in various psychiatric disorders, including but not limited to, progressive, deteriorating forms of Bipolar disorder or Schizoaffective disorder or Schizophrenia, Impulse Control disorders, Obsessive Compulsive disorder (OCD), behavioral changes in Temporal Lobe Epilepsy and personality disorders.
  • psychiatric disorders including but not limited to, progressive, deteriorating forms of Bipolar disorder or Schizoaffective disorder or Schizophrenia, Impulse Control disorders, Obsessive Compulsive disorder (OCD), behavioral changes in Temporal Lobe Epilepsy and personality disorders.
  • the compounds of the invention would be used to provide neuroprotection in disorders involving trauma and progressive injury to the nervous system in various psychiatric disorders. These disorders would be selected form the group consisting of; Schizoaffective disorder, Schizophrenia, Impulse Control disorders, Obsessive Compulsive disorder (OCD) and personality disorders.
  • trauma and injury make take the form of disorders associated with overt and extensive memory loss including, but not limited to, neurodegenerative disorders associated with age-related dementia, vascular dementia, diffuse white matter disease (Binswanger's disease), dementia of endocrine or metabolic origin, dementia of head trauma and diffuse brain damage, dementia pugilistica or frontal lobe dementia, including but not limited to Pick's Disease.
  • neurodegenerative disorders associated with age-related dementia vascular dementia, diffuse white matter disease (Binswanger's disease), dementia of endocrine or metabolic origin, dementia of head trauma and diffuse brain damage, dementia pugilistica or frontal lobe dementia, including but not limited to Pick's Disease.
  • disorders associated with neuronal injury include, but are not limited to, disorders associated with chemical, toxic, infectious and radiation injury of the nervous system including the retina, injury during fetal development, prematurity at time of birth, anoxic-ischemia, injury from hepatic, glycemic, uremic, electrolyte and endocrine origin, injury of psychiatric origin (including, but not limited to, psychopathology, depression or anxiety), injury from peripheral diseases and plexopathies (including plexus palsies) or injury from neuropathy (including neuropathy selected from multifocal, sensory, motor, sensory-motor, autonomic, sensory-autonomic or demyelinating neuropathies (including, but not limited to Guillain-Barre syndrome or chronic inflammatory demyelinating polyradiculoneuropathy) or those neuropathies originating from infections, inflammation, immune disorders, drug abuse, pharmacological treatments, toxins, trauma (including, but not limited to compression, crush, laceration or segmentation traumas), metabolic disorders (including, but
  • the term "neuroprotection” as used herein shall mean; inhibiting, preventing, ameliorating or reducing the severity of the dysfunction, degeneration or death of nerve cells, axons or their supporting cells in the central or peripheral nervous system of a mammal, including a human.
  • This includes the treatment or prophylaxis of a neurodegenerative disease; protection against excitotoxicity or ameliorating the cytotoxic effect of a compound (for example, a excitatory amino acid such as glutamate; a toxin; or a prophylactic or therapeutic compound that exerts an immediate or delayed cytotoxic side effect including but not limited to the immediate or delayed induction of apoptosis) in a patient in need thereof.
  • a compound for example, a excitatory amino acid such as glutamate; a toxin; or a prophylactic or therapeutic compound that exerts an immediate or delayed cytotoxic side effect including but not limited to the immediate or delayed induction of apoptosis
  • a patient in need of treatment with a neuroprotective drug will refer to any patient who currently has or may develop any of the above syndromes or disorders, or any disorder in which the patient's present clinical condition or prognosis could 005/036695
  • antiepileptic drug (AED) will be used interchangeably with the term “anticonvulsant agent,” and as used herein, both terms refer to an agent capable of inhibiting (e.g., preventing slowing, halting, or reversing) seizure activity or ictogenesis when the agent is administered to a subject or patient.
  • treating refers to any indicia of success in the prevention or amelioration of an injury, pathology or condition, including any objective or subjective parameter such as abatement; remission; diminishing of symptoms or making the injury, pathology, or condition more tolerable to the patient; slowing in the rate of degeneration or decline; making the final point of degeneration less debilitating; or improving a subject's physical or mental well-being.
  • the treatment or amelioration of symptoms can be based on objective or subjective parameters; including the results of a physical examination, neurological examination, and/or psychiatric evaluations.
  • treating includes the administration of the compounds or agents of the present invention to provide neuroprotection.
  • treatment with the compounds of the present invention will done in combination with other neuroprotective compounds or AED's to prevent, inhibit, or arrest the progression of neuronal death or damage or brain dysfunction or brain hyperexcitability.
  • therapeutic effect refers to the effective provision of neuroprotection effects to prevent or minimize the death or damage or dysfunction of the cells of the patient's central or peripheral nervous system.
  • a therapeutically effective amount means a sufficient amount of one or more of the compounds of the invention to produce a therapeutic effect, as defined above, in a subject or patient in need of such neuroprotection treatment.
  • subject or “patient” are used herein interchangeably and as used herein mean any mammal including but not limited to human beings T/US2005/036695
  • the methods of the present invention will be advantageously used to treat a patient who is not suffering or known to be suffering from a condition that is known in the art to be effectively treated with carbamate compounds or presently known neuroprotective compounds or AEDs. In these cases the decision to use the methods and compounds of the present invention would be made on the basis of determining if the patient is a "patient in need of treatment with a neuroprotective drug (NPD)", as that term is defined above.
  • NPD neuroprotective drug
  • this invention provides methods of neuroprotection.
  • these methods comprise administering a therapeutically effective amount of a carbamate compound of the invention to a patient who has not yet developed overt, clinical signs or symptoms of injury or damage to the cells of the nervous system but who may be in a high risk group for the development of neuronal damage because of injury or trauma to the nervous system or because of some known predisposition either biochemical or genetic or the finding of a verified biomarker of one or more of these disorders.
  • the methods and compositions of the present invention are directed toward neuroprotection in a subject who is at risk of developing neuronal damage but who has not yet developed clinical evidence.
  • This patient may simply be at "greater risk” as determined by the recognition of any factor in a subject's, or their families, medical history, physical exam or testing that is indicative of a greater than average risk for developing neuronal damage. Therefore, this determination that a patient may be at a "greater risk" by any available means can be used to determine whether the patient should be treated with the methods of the present invention.
  • subjects who may benefit from treatment by the methods and compounds of this invention can be identified using accepted screening methods to determine risk factors for neuronal damage.
  • screening methods include, for example, conventional work-ups to determine risk factors including but not limited to:, for example, head trauma, either closed or penetrating, CNS infections, bacterial or viral, cerebrovascular disease including but not limited to stroke, brain tumors, brain edema, cysticercosis, porphyria, metabolic encephalopathy, drug withdrawal including but not limited to sedative-hypnotic or alcohol withdrawal, abnormal perinatal history including anoxia at birth or birth injury of any kind, cerebral palsy, learning disabilities, hyperactivity, history of febrile convulsions as a child, history of status epilepticus, family history of epilepsy or any a seizure related disorder, inflammatory disease of the brain including lupis, drug intoxication either direct or by placental transfer, including but not limited to cocaine poisoning, parental consanguinity, and treatment with
  • NPD in patients who have no clinical signs or symptoms may be based on a variety of "surrogate markers” or “biomarkers”.
  • the terms “surrogate marker” and “biomarker” are used interchangeably and refer to any anatomical, biochemical, structural, electrical, genetic or chemical indicator or marker that can be reliably correlated with the present existence or future development of neuronal damage.
  • brain-imaging techniques such as computer tomography (CT), magnetic resonance imaging (MRI) or positron emission tomography (PET), can be used to determine whether a subject is at risk for neuronal damage.
  • Suitable biomarkers for the methods of this invention include, but are not limited to: the determination by MRI, CT or other imaging techniques, of sclerosis, atrophy or volume loss in the hippocampus or overt mesial temporal sclerosis (MTS) or similar relevant anatomical pathology; the detection in the patient's blood, serum or tissues of a molecular species such as a protein or other biochemical biomarker, e.g., elevated levels of ciliary neurotrophic factor (CNTF) or elevated serum levels of a neuronal degradation product; or other evidence from surrogate markers or biomarkers that the patient is in need of treatment with a neuroprotective drug.
  • CNTF ciliary neurotrophic factor
  • a determination that a subject has, or may be at risk for developing, neuronal damage would also include, for example, a medical evaluation that includes a thorough history, a physical examination, and a series of relevant bloods tests. It can also include an electroencephalogram (EEG), CT, MRI or PET scan.
  • EEG electroencephalogram
  • a determination of an increased risk of developing neuronal damage or injury may also be made by means of genetic testing, including gene expression profiling or proteomic techniques.
  • a neuroprotective drug e.g., Bipolar Disorder, Schizoaffective disorder, Schizophrenia, Impulse Control Disorders, etc.
  • the above tests may also include a present state exam and a detailed history of the course of the patients symptoms such as mood disorder symptoms and psychotic symptoms over time and in relation to other treatments the patient may have received over time, e.g., a life chart.
  • carbamate compounds suitable for use in the practice of this invention will be administered either singly or concomitantly with at least one or more other compounds or therapeutic agents, e.g., with other neuroprotective drugs or antiepileptic drugs, anticonvulsant drugs.
  • the present invention provides methods to treat or prevent neuronal injury in a patient. The method includes the step of; administering to a patient in need of treatment, an effective amount of one of the carbamate compounds disclosed herein in combination with an effective amount of one or more other compounds or therapeutic agents that 2005/036695
  • concomitant administration or “combination administration” of a compound, therapeutic agent or known drug with a compound of the present invention means administration of the drug and the one or more compounds at such time that both the known drug and the compound will have a therapeutic effect. In some cases this therapeutic effect will be synergistic.
  • concomitant administration can involve concurrent (i.e. at the same time), prior, or subsequent administration of the drug with respect to the administration of a compound of the present invention.
  • a person of ordinary skill in the art would have no difficulty determining the appropriate timing, sequence and dosages of administration for particular drugs and compounds of the present invention.
  • the said one or more other compounds or therapeutic agents may be selected from compounds that have one or more of the following properties: antioxidant activity; NMDA receptor antagonist activity, augmentation of endogenous GABA inhibition; NO synthase inhibitor activity; iron binding ability, e.g., an iron chelator; calcium binding ability, e.g., a Ca (II) chelator; zinc binding ability, e.g., a Zn (II) chelator; the ability to effectively block sodium or calcium ion channels, or to open potassium or chloride ion channels in the CNS of a patient.
  • the one or more other compounds or therapeutic agents would antagonize NMDA receptors by binding to the NMDA receptors (e.g., by binding to the glycine binding site of the NMDA receptors) and/or the agent would augment GABA inhibition by decreasing glial GABA uptake.
  • the said one or more other compounds or therapeutic agents may be any agent known to suppress seizure activity even if that compound is not known to provide neuroprotection.
  • agents would include but not be limited to any effective AED known to one of skill in the art or discovered in the future, for example suitable agents include, but are not limited to; carbamazepine, clobazam, clonazepam, ethosuximide, felbamate, gabapentin, 5 036695
  • the compounds of this invention will be used, either alone or in combination with each other or in combination with one or more other therapeutic medications as described above, or their salts or esters, for manufacturing a medicament for the purpose of providing neuroprotection to a patient or subject in need thereof.
  • the present invention provides enantiomeric mixtures and isolated enantiomers of Formula 1 and/or Formula 2 as pharmaceuticals.
  • the carbamate compounds are formulated as pharmaceuticals to provide neuroprotection in a subject.
  • the carbamate compounds of the present invention can be administered as pharmaceutical compositions by any method known in the art for administering therapeutic drugs including oral, buccal, topical, systemic (e.g., transdermal, intranasal, or by suppository), or parenteral (e.g., intramuscular, subcutaneous, or intravenous injection.)
  • Administration of the compounds directly to the nervous system can include, for example, administration to intracerebral, intraventricular, intacerebroventricular, intrathecal, intracisternal, intraspinal or peri-spinal routes of administration by delivery via intracranial or intravertebral needles or catheters with or without pump devices.
  • the compounds of the present invention can be administered by means of direct exogenous application to the eye, i.e., to the sclera or otherwise, e.g., eye drops or by ocular implant or other slow delivery device including microspheres including by direct injection into the vitreous humor etc..
  • compositions can take the form of tablets, pills, capsules, semisolids, powders, sustained release formulations, solutions, suspensions, emulsions, syrups, elixirs, aerosols, or any other appropriate compositions; and comprise at least one compound of this invention in combination with at least one pharmaceutically acceptable excipient.
  • Suitable excipients are well known to persons of ordinary skill in the art, and they, and the methods of formulating the compositions, can be found in such standard references as Alfonso AR: Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton PA, 1985, the disclosure of which is incorporated herein by reference in its entirety and for all purposes.
  • Suitable liquid carriers, especially for injectable solutions include water, aqueous saline solution, aqueous dextrose solution, and glycols.
  • the carbamate compounds can be provided as aqueous suspensions.
  • Aqueous suspensions of the invention can contain a carbamate compound in admixture with excipients suitable for the manufacture of aqueous suspensions.
  • excipients can include, for example, a suspending agent, such as sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia, and dispersing or wetting agents such as a naturally occurring phosphatide (e.g., lecithin), a condensation product of an alkylene oxide with a fatty acid (e.g., polyoxyethylene stearate), a condensation product of ethylene oxide with a long chain aliphatic alcohol (e.g., heptadecaethylene oxycetanol), a condensation product of ethylene oxide with a partial ester derived from a fatty acid and a hexitol (e.g., polyoxyethylene sorbitol mono-oleate), or a
  • the aqueous suspension can also contain one or more preservatives such as ethyl or n-propyl p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose, aspartame or saccharin.
  • Formulations can be adjusted for osmolarity.
  • Oil suspensions for use in the present methods can be formulated by suspending a carbamate compound in a vegetable oil, such as arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin; or a mixture of these.
  • the oil suspensions can contain a thickening agent, such as beeswax, hard paraffin or cetyl alcohol.
  • Sweetening agents can be added to provide a palatable oral preparation, such as glycerol, sorbitol or sucrose. These formulations can be preserved by the addition of an antioxidant such as ascorbic acid.
  • an injectable oil vehicle see Minto, J. Pharmacol. Exp. Ther. 281 :93-102, 1997.
  • the pharmaceutical formulations of the invention can also be in the form of oil-in-water emulsions.
  • the oily phase can be a vegetable oil or a mineral oil, described above, or a mixture of these.
  • Suitable emulsifying agents include naturally occurring gums, such as gum acacia and gum tragacanth, naturally occurring phosphatides, such as soybean lecithin, esters or partial esters derived from fatty acids and hexitol anhydrides, such as sorbitan mono-oleate, and condensation products of these partial esters with ethylene oxide, such as polyoxyethylene sorbitan mono- oleate.
  • the emulsion can also contain sweetening agents and flavoring agents, as in the formulation of syrups and elixirs. Such formulations can also contain a demulcent, a preservative, or a coloring agent.
  • Aerosol formulations i.e., they can be "nebulized" to be administered via inhalation. Aerosol formulations can be placed into pressurized acceptable propellants, such as dichlorodifluoromethane, propane, nitrogen, and the like.
  • Formulations of the present invention suitable for parenteral administration can include aqueous and non-aqueous, isotonic sterile injection solutions, which can contain antioxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient, and aqueous and non-aqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents, stabilizers, and preservatives.
  • aqueous and non-aqueous sterile suspensions can include suspending agents, solubilizers, thickening agents, stabilizers, and preservatives.
  • acceptable vehicles and solvents that can be employed are water and Ringer's solution, an isotonic sodium chloride.
  • sterile fixed oils can conventionally be employed as a solvent or suspending medium.
  • any bland fixed oil can be employed including synthetic mono- or diglycerides.
  • fatty acids such as oleic acid can likewise be used in the preparation of injectables. These solutions are sterile and generally free of undesirable matter.
  • the compounds are sufficiently soluble they can be dissolved directly in normal saline with or without the use of suitable organic solvents, such as propylene glycol or polyethylene glycol. Dispersions of the finely divided compounds can be made-up in aqueous starch or sodium carboxymethyl cellulose solution, or in suitable oil, such as arachis oil. These formulations can be sterilized by conventional, well-known sterilization techniques.
  • the formulations can contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions such as pH adjusting and buffering agents, toxicity adjusting agents, e.g., sodium acetate, sodium chloride, potassium chloride, calcium chloride, sodium lactate and the like.
  • the concentration of a carbamate compound in these formulations can vary widely, and will be selected primarily based on fluid volumes, viscosities, body weight, and the like, in accordance with the particular mode of administration selected and the patient's needs.
  • the formulation can be a sterile injectable preparation, such as a sterile injectable aqueous or oleaginous suspension.
  • This suspension can be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents.
  • the sterile injectable preparation can also be a sterile injectable solution or suspension in a nontoxic parenterally acceptable diluents or solvent, such as a solution of 1 ,3-butanediol.
  • the formulations of commends can be presented in unit-dose or multi-dose sealed containers, such as ampoules and vials.
  • Injection solutions and suspensions can be prepared from sterile powders, granules, and tablets of the kind previously described.
  • a carbamate compound suitable for use in the practice of this invention can be and is preferably administered orally.
  • the amount of a compound of the present invention in the composition can vary widely depending on the type of composition, size of a unit dosage, kind of excipients, and other factors well known to those of ordinary skill in the art.
  • the final composition can comprise, for example, from 0.000001 percent by weight (% w) to 10 % w of the carbamate compound, preferably 0.00001 % w to 1 % w, with the remainder being the excipient or excipients.
  • compositions for oral administration can be formulated using pharmaceutically acceptable carriers well known in the art in dosages suitable for oral administration.
  • Such carriers enable the pharmaceutical formulations to be formulated in unit dosage forms as tablets, pills, powder, dragees, capsules, liquids, lozenges, gels, syrups, slurries, suspensions, etc. suitable for ingestion by the patient.
  • Formulations suitable for oral administration can consist of (a) liquid solutions, such as an effective amount of the pharmaceutical formulation suspended in a diluents, such as water, saline or PEG 400; (b) capsules, sachets or tablets, each containing a predetermined amount of the active ingredient, as liquids, solids, granules or gelatin; (c) suspensions in an appropriate liquid; and (d) suitable emulsions.
  • a diluents such as water, saline or PEG 400
  • capsules, sachets or tablets each containing a predetermined amount of the active ingredient, as liquids, solids, granules or gelatin
  • suspensions in an appropriate liquid such as water, saline or PEG 400
  • compositions for oral use can be obtained through combination of the compounds of the present invention with a solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable additional compounds, if desired, to obtain tablets or dragee cores.
  • Suitable solid excipients are carbohydrate or protein fillers and include, but are not limited to sugars, including lactose, sucrose, mannitol, or sorbitol; starch from com, wheat, rice, potato, or other plants; cellulose such as methyl cellulose, hydroxymethyl cellulose, hydroxypropylmethyl-cellulose or sodium carboxymethylcellulose; and gums including arabic and tragacanth; as well as proteins such as gelatin and collagen.
  • disintegrating or solubilizing agents can be added, such as the cross-linked polyvinyl pyrrolidone, agar, alginic acid, or a salt thereof, such as sodium alginate.
  • Tablet forms can include one or more of lactose, sucrose, mannitol, sorbitol, calcium phosphates, com starch, potato starch, microcrystalline cellulose, gelatin, colloidal silicon dioxide, talc, magnesium stearate, stearic acid, and other excipients, colorants, fillers, binders, diluents, buffering agents, moistening agents, preservatives, flavoring agents, dyes, disintegrating agents, and pharmaceutically compatible carriers.
  • Lozenge forms can comprise the active ingredient in a flavor, e.g., sucrose, as well as pastilles comprising the active ingredient in an inert base, such as gelatin and glycerin or sucrose and acacia emulsions, gels, and the like containing, in addition to the active ingredient, carriers known in the art.
  • a flavor e.g., sucrose
  • an inert base such as gelatin and glycerin or sucrose and acacia emulsions, gels, and the like containing, in addition to the active ingredient, carriers known in the art.
  • the compounds of the present invention can also be administered in the form of suppositories for rectal administration of the drug.
  • These formulations can be prepared by mixing the drug with a suitable non-irritating excipient that is solid at ordinary temperatures but liquid at the rectal temperatures and will therefore melt in the rectum to release the drug.
  • suitable non-irritating excipient that is solid at ordinary temperatures but liquid at the rectal temperatures and will therefore melt in the rectum to release the drug.
  • Such materials are cocoa butter and polyethylene glycols.
  • the compounds of the present invention can also be administered by intranasal, intraocular, intravaginal, and intrarectal routes including suppositories, insufflation, powders and aerosol formulations (for examples of steroid inhalants, see Rohatagi, J. Clin. Pharmacol. 35:1187-1193, 1995; Tjwa, Ann. Allergy Asthma Immunol. 75:107-111 , 1995).
  • the compounds of the present invention can be delivered transdermal ⁇ , by a topical route, formulated as applicator sticks, solutions, suspensions, emulsions, gels, creams, ointments, pastes, jellies, paints, powders, and aerosols.
  • Encapsulating materials can also be employed with the compounds of the present invention and the term "composition" can include the active ingredient in combination with an encapsulating material as a formulation, with or without other carriers.
  • the compounds of the present invention can also be delivered as microspheres for slow release in the body.
  • microspheres can be administered via intradermal injection of drug (e.g., mifepristone)-containing microspheres, which slowly release subcutaneously (see Rao, J. Biomater Sci. Polym. Ed. 7:623-645, 1995; as biodegradable and injectable gel formulations (see, e.g., Gao, Pharm. Res.
  • transdermal and intradermal routes afford constant delivery for weeks or months.
  • Cachets can also be used in the delivery of the compounds of the present invention.
  • the compounds of the present invention can be delivered by the use of liposomes which fuse with the cellular membrane or are endocytosed, i.e., by employing ligands attached to the liposome that bind to surface membrane protein receptors of the cell resulting in endocytosis.
  • liposomes particularly where the liposome surface carries ligands specific for target cells, or are otherwise preferentially directed to a specific organ, one can focus the delivery of the carbamate compound into target cells in vivo.
  • liposomes particularly where the liposome surface carries ligands specific for target cells, or are otherwise preferentially directed to a specific organ, one can focus the delivery of the carbamate compound into target cells in vivo.
  • the pharmaceutical formulations of the invention can be provided as a salt and can be formed with many acids, including but not limited to hydrochloric, sulfuric, acetic, lactic, tartaric, malic, succinic, etc. Salts tend to be more soluble in aqueous or other protonic solvents that are the corresponding free base forms.
  • the preferred preparation can be a lyophilized powder which can contain, for example, any or all of the following: 1 mM-50 mM histidine, 0.1%-2% sucrose, 2%-7% mannitol, at a pH range of 4.5 to 5.5, that is combined with buffer prior to use.
  • Pharmaceutically acceptable salts and esters refers to salts and esters that are pharmaceutically acceptable and have the desired pharmacological properties. Such salts include salts that may be formed where acidic protons present in the compounds are capable of reacting with inorganic or organic bases. Suitable inorganic salts include those formed with the alkali metals, e.g. sodium and potassium, magnesium, calcium, and aluminum. Suitable organic salts include those formed with organic bases such as the amine bases, e.g. ethanolamine, diethanolamine, triethanolamine, tromethamine, N methylglucamine, and the like. Pharmaceutically acceptable salts can also include acid addition salts formed from the reaction of amine moieties in the parent compound with inorganic acids (e.g.
  • esters include esters formed from carboxy, sulfonyloxy, and phosphonoxy groups present in the compounds.
  • a pharmaceutically acceptable salt or ester may be a mono-acid-mono-salt or ester or a di-salt or ester; and similarly where there are more than two acidic groups present, some or all of such groups can be salified or esterified.
  • Compounds named in this invention can be present in unsalified or unesterified form, or in salified and/or esterified form, and the naming of such compounds is intended to include both the original (unsalified and unesterified) compound and its pharmaceutically acceptable salts and esters.
  • the present invention includes pharmaceutically acceptable salt and ester forms of Formula 1 and Formula 2. More than one crystal form of an enantiomer of Formula 1 or Formula 2 can exist and as such are also included in the present invention.
  • a pharmaceutical composition of the invention can optionally contain, in addition to a carbamate compound, at least one other therapeutic agent useful in the treatment of a disease or condition associated with providing neuroprotection.
  • the pharmaceutical compositions are generally formulated as sterile, substantially isotonic and in full compliance with all Good Manufacturing Practice (GMP) regulations of the U.S. Food and Drug Administration.
  • GMP Good Manufacturing Practice
  • the present invention provides methods of providing neuroprotection in a mammal, including a human subject or patient, using the carbamate compounds or compositions of the invention.
  • the amount of the carbamate compound necessary to provide neuroprotection is defined as a therapeutically or a pharmaceutically effective dose.
  • the dosage schedule and amounts effective for this use, i.e., the dosing or dosage regimen will depend on a variety of factors including the stage of the disease, the patient's physical status, age and the like. In calculating the dosage regimen for a patient, the mode of administration is also taken into account. In order to accomplish this objective the compounds or compositions of this invention must be used in the correct therapeutically effective amount or dose, as described below
  • the dosage schedule and amounts effective for this use i.e., the dosing or dosage regimen, will depend on a variety of factors including the precise nature of the disease or injury, the patient's physical status, weight, age and the like. In calculating the dosage regimen for a patient, the mode of administration is also taken into account.
  • Test Compound i.e., Formula 7
  • Example 2 The doses tested in rats for anti-epileptogenic and neuroprotective effects in Example 2 ranged from 30 mg/kg/day to 120 mg/kg/day.
  • the lowest dose tested in this Example i.e., 30 mg/kg, produced some measurable protective effects while the lowest dose tested in Example 1 was 10 mg/kg/day and produced minimal protective effects (See Examples 1 and 2 below).
  • Test Compound (TC) In rats, doses of 30 mg/kg/day of Test Compound (TC) would be expected to produce blood levels of; C max of 9.33 micrograms/mL and an
  • AUC of 97.32 micrograms-hour/mL In humans, these blood levels would be expected from doses of about 500 mg/day to about 600 mg/day or from about
  • Example 1 relatively high doses and blood levels were required because of the acute and very severe animal model that was used and the need to produce the neuroprotective anti-epileptogenic effects demonstrated.
  • the compound was given after the traumatic event or injury had occurred, i. e., the induction of status epilepticus by administration of Li-Pilocarpine.
  • the transient cerebral ischemia middle cerebral artery occlusion (MCAO) rat model in Example 4 the compound was also administered 1 hour after the occlusion of the middle cerebral artery.
  • MCAO transient cerebral ischemia middle cerebral artery occlusion
  • This type of post injury model is likely to correlate to analogously acute and severe clinical situations in human patients such as not starting the medication until after severe CNS injury has already occurred. In such situations, it is expected that the dosages needed for a neuroprotective and antiepileptogenic effect will be higher than what would likely be needed in less acute or severe circumstances or in chronic situations and especially where the medication is used prophylactically.
  • the required doses and blood levels required to produce clinically important neuroprotective effects would be expected to be somewhat lower than the human equivalent of the 10 mg/kg dose used in Example 4 and significantly lower than the 30 mg/kg/day dose found effective in Examples 2.
  • the doses expected to be therapeutically effective in clinical practice in humans, in most cases, would be less than that identified in these severe animal models.
  • the ED50 for Test Compound for preventing seizures in rats is about 4 mg/kg to about 30 mg/kg (depending on the time and experiment type) so a minimum effective dose of 10 mg/kg in the neuroprotection rat models is not unexpected.
  • an expected effective neuroprotective human dose would be similar to the minimum dose required for anticonvulsant efficacy in humans.
  • the effective doses and blood levels in humans would be expected to be somewhat lower than human equivalent of the 10 mg/kg dose found minimally effective in the transient cerebral ischemia middle cerebral artery occlusion (MCAO) rat model in Example 4.
  • MCAO transient cerebral ischemia middle cerebral artery occlusion
  • the lower limits of a neuroprotective effective dose would be expected to be about 100 mg/day to about 200 mg/day or about 1.43 mg/kg/day to about 2.85 mg/kg/day in a 70 kg. human, producing an expected C max (at 200 mg/day) of about 3.6-micrograms/mL and AUC of about 42.2 micrograms- hour/mL
  • the dose range would be expected to be somewhat higher, for example, from about 200 mg/day to about 400 mg/day or about 2.85 to about 5.71 mg/kg/day in a 70 kg human.
  • the compounds and compositions of the invention do not have a theoretical upper end to their clinically effective dose range. Thus, the upper end of the therapeutically effective range would be determined by the maximum amount that could be tolerated by the patient.
  • the highest dose tested in rats i.e., 120 mg/kg, which showed very marked neuroprotective and anti-epileptogenesis effects, would be expected, on the basis of the data above, to have a C max and AUC similar or below those produced in humans at a dose of 750 mg twice a day (1500 mg/day or approximately 21.4 mg/kg/day).
  • a dose of 750 mg twice a day (total daily dose of 1500 mg) has been used in humans and found to be easily tolerated.
  • the maximum tolerable dose would be considerably higher than this for many patients, perhaps 2500 mg/day to 3000 mg/day or about 35.7 mg/kg/day to about 42.9 mg/kg/day in a 70 kg human.
  • the pharmaceutical compounds and compositions of the invention may be administered at a dosage of from about 1.4 mg/kg/day to about 43.0 mg/kg/day (100 mg/day to 3000 mg/day in a 70 kg human), preferably from about 2.9 mg/kg/day to about 35.7 mg/kg/day (200 mg/day to 2500 mg/day in a 70 kg human), more preferably from about 3.6 mg/kg/day to about 28.6 mg/kg/day (250 mg/day to 2000 mg/day in a 70 kg human), or even more preferably from about 4.3 mg/kg/day to about 21.4 mg/kg/day (300 mg/day to 1500 mg/day in a 70 kg human) or most preferably from about 5.0 mg/kg/day to about 17.1 mg/kg/day (350 mg/day to 1200 mg/day in a 70 kg human).
  • These dosages may be varied depending the individual 95
  • a therapeutically effective dose or amount of a particular substituted carbamate compound of the invention for treating epilepsy and for producing a clinically significant neuroprotective effect see, e.g., Lieberman, Pharmaceutical Dosage Forms(Vols. 1-3, 1992); Lloyd, 1999, The art, Science and Technology of Pharmaceutical Compounding; and Pickar, 1999, Dosage Calculations).
  • a therapeutically effective dose is also one in which any toxic or detrimental side effects of the active agent is outweighed in clinical terms by therapeutically beneficial effects.
  • compositions of this invention could be initiated at a low or moderate dose and then increased to a fully therapeutically effective dose and blood level over a period of time.
  • compositions or compounds disclosed herein can be administered to the subject in a single bolus delivery, via continuous delivery over an extended time period, or in a repeated administration protocol (e.g., by an hourly, daily or weekly, repeated administration protocol).
  • the pharmaceutical formulations of the present invention can be administered, for example, one, two or more times daily, 3 times per week, or weekly. In one embodiment of the present invention, the pharmaceutical formulations of the present invention are orally administered once or twice daily.
  • a treatment regimen with the compounds of the present invention can commence, for example, after a subject suffers from a brain damaging injury or other initial insult such as a stroke.
  • a treatment regimen with the compounds of the present invention can commence before any damage or injury to the nervous system has occurred but at a time when such damage or injury can expected or is likely to occur.
  • such a treatment regimen can begin before a subject undergoes a neurosurgical procedure or is likely to suffer other forms or head or brain trauma, e.g., combat, violent sports or racing, recurrent strokes, TIA's etc.
  • the carbamate compounds of the invention can be administered daily for a set period of time (week, month, year) after occurrence of the brain damaging injury or initial insult.
  • An attendant physician will know how to determine that the carbamate compound has reached a therapeutically effective level, e.g., clinical exam of a patient, or by measuring drug levels in the blood or cerebro-spinal fluid.
  • a therapeutically effective level e.g., clinical exam of a patient, or by measuring drug levels in the blood or cerebro-spinal fluid.
  • One of skill in the art would be able to determine the maximum tolerable dose by means of a physical examination to determine the presence and severity of side effects such as slurred speech, lethargy or impaired coordination.
  • a therapeutically effective dosage of the biologically active agent(s) can include repeated doses within a prolonged treatment regimen that will yield clinically significant results to provide a neuroprotective effect. Determination of effective dosages in this context is typically based on animal model studies followed up by human clinical trials and is guided by determining effective dosages and administration protocols that significantly reduce the occurrence or severity of targeted exposure symptoms or conditions in the subject. Suitable models in this regard include, for example, murine, rat, porcine, feline, non-human primate, and other accepted animal model subjects known in the art.
  • effective dosages can be determined using in vitro models (e.g., immunologic and histopathologic assays). Using such models, only ordinary calculations and adjustments are typically required to determine an appropriate concentration and dose to administer a therapeutically effective amount of the biologically active agent(s) (e.g., amounts that are intranasally effective, transdermally effective, intravenously effective, or intramuscularly effective to elicit a desired response).
  • in vitro models e.g., immunologic and histopathologic assays.
  • a therapeutically effective amount of the biologically active agent(s) e.g., amounts that are intranasally effective, transdermally effective, intravenously effective, or intramuscularly effective to elicit a desired response.
  • unit dosage forms of the compounds are prepared for standard administration regimens.
  • the composition can be subdivided readily into smaller doses at the physician's direction.
  • unit dosages can be made up in packeted powders, vials or ampoules and preferably in capsule or tablet form.
  • the active compound present in these unit dosage forms of the composition can be present in an amount of, for example, from about 25 mg. to about 800 mg or preferably in unit dosage amounts of about; 50, 100, 200 250, 400, 450, 500, and 600 mg of one or more of the active carbamate compounds of the invention, for single or multiple daily administration, according to the particular need of the patient.
  • kits for use in providing neuroprotection After a pharmaceutical composition comprising one or more carbamate compounds of this invention, with the possible addition of one or more other compounds of therapeutic benefit, has been formulated in a suitable carrier, it can be placed in an appropriate container and labeled for providing neuroprotection. Additionally, another pharmaceutical comprising at least one other therapeutic agent useful in providing neuroprotection, treatment of epileptogenesis, epilepsy or another disorder or condition associated with neuronal injury can be placed in the container as well and labeled for treatment of the indicated disease. Such labeling can include, for example, instructions concerning the amount, frequency and method of administration of each pharmaceutical.
  • Example 1 The lithium-pilocarpine model of temporal lobe epilepsy
  • This acute seizure period is followed by a "silent" seizure-free phase lasting for a mean duration of 14-25 days after which all animals exhibit spontaneous recurrent convulsive seizures at the usual frequency of 2 to 5 per week (Turski et al., 1989, Synapse 3:154-171 ; Cavalheiro, 1995, ltal J Neurol Sci 16:33-37; Dube et al., 2001 , Exp Neurol 167:227-241). Lithium-pilocarpine and treatments with the test compound Male Wistar rats weighing 225-250 g, provided by Janvier Breeding Center
  • the animals of the first group received 10 mg/kg of the test compound, i.p., 1 h after the onset of SE (pilo-TC10) while the animals of groups 2 and 3 received 30 and 60 mg/kg of the Test Compound (pilo-TC30 and pilo-TC60), respectively.
  • Another group was injected with 2 mg/kg diazepam (DZP, i.m.) at 1 h after the onset of SE which are our standard treatment to improve animals survival after SE (pilo-DZP).
  • the control group received saline instead of pilocarpine and the Test Compound (saline-saline).
  • the pilo-Test Compound rats surviving SE were then injected about 10 h after the first test compound injection with a second i.p. injection of the same dose of the test compound and were maintained under a twice daily treatment with the test compound for 6 additional days.
  • PiIo-DZP received a second injection of 1 mg/kg DZP on the day of SE at about 10 h after the first one.
  • Pilo- DZP and saline-saline rats received twice daily an equivalent volume of saline.
  • the effects of the test compound on the EEG and on the latency to occurrence of SRS were investigated by daily video recording of the animals for 10 h per day and the recording of the electrographic activity twice a week for ⁇ h. Quantification of cell densities Quantification of cell densities was performed at 6 days after SE on 8 pilo-DZP, 8 pilo-TC10, 7 pilo-TC30, 7 pilo-TC60, and 6 saline-saline rats.
  • ⁇ Cell counts were performed twice in a blind manner and were the average of at least 3 values from 2 adjacent sections in each individual animal. Counts involved only cells larger than 10 ⁇ m, smaller ones being considered as glial cells. Timm staining
  • mossy fiber sprouting was examined on rats in the chronic period exposed to the test compound or DZP and in 3 saline-saline rats.
  • Animals were deeply anaesthetized and perfused transcardially with saline followed by 100 ml of 1.15% (w/v) Na 2 S in 0.1 M phosphate buffer, and 100 ml of 4% (v/v) formaldehyde in 0.1 M phosphate buffer.
  • Brains were removed from skull, post-fixed in 4% formaldehyde during 3-5 h and 40 ⁇ m sections were cut on a sliding vibratome and mounted on gelatin-coated slides.
  • Mossy fiber sprouting was evaluated according to criteria previously described in dorsal hippocampus (Cavazos et al., 1991 , J Neurosci 11 :2795- 2803.), which are follows: 0 - no granules between the tips and crest of the DG; 1 - sparse granules in the supragranular region in a patchy distribution between the tips and crest of DG; 2 - more numerous granules in a continuous distribution between the tips and crest of DG; 3 - prominent granules in a continuous pattern between tips and crest, with occasional patches of confluent granules between tips and crest; 4 - prominent granules that form a confluent dense laminar band between tips and crest and 5 - confluent dense laminar band of granules that extends into the inner molecular layer. Data analysis
  • the EEG patterns during the silent period were similar in pilo-DZP and pilo-TC10, 30 or 60 rats.
  • the baseline EEG was still characterized by the occurrence of PEDs on which large waves or spikes could be superimposed.
  • the frequency and amplitude of PEDs decreased as soon as 10 min after injection and were replaced by spikes of large amplitude in the TC30 group and of low amplitude in the TC60 group.
  • the EEG had returned to baseline levels in the two latter groups.
  • stage III SRS spontaneous recurrent seizures
  • stage IV-V SRS The frequency of more severe stage IV-V SRS was highest during the first week in most groups, except pilo-TC30 and TC60 with late seizure onset where the SRS frequency was constant over the whole 4 weeks in TC30 group and over the first two weeks in the pilo-TC60 group with late SRS onset in which no stage IV-V seizures where no seizures recorded after the second week.
  • the frequency of stage IV-V SRS was significantly reduced in the TC10, TC30 and TC60 (with early SRS onset) groups (2.3-6,1 SRS per week) compared to the pilo-DZP group (11.3 SRS per week) during the first week.
  • stage IV-V SRS was reduced in all groups compared to the first week reaching values of 2-6 seizures per week, except in the pilo-TC60 group with early SRS onset where the frequency of seizures was significantly reduced to 0.6-0.9 seizure per week compared to the pilo-DZP group in which the frequency of SRS ranged from 3.3 to 5.8.
  • Cell densities in hippocampus, thalamus and cortex were significantly reduced in all groups compared to the first week reaching values of 2-6 seizures per week, except in the pilo-TC60 group with early SRS onset where the frequency of seizures was significantly reduced to 0.6-0.9 seizure per week compared to the pilo-DZP group in which the frequency of SRS ranged from 3.3 to 5.8.
  • pilo-DZP rats compared to saline-saline rats, the number of cells was massively decreased in the CA1 region of the hippocampus (70% cell loss in the pyramidal cell layer) while the CAS region was less extensively damaged (54% cell loss in CA3a and 31 % in CA3b).
  • the pilo-DZP rats experienced extensive cell loss in the hilus (73%) while the granule cell layer did not show visible damage. Similar damage was observed in the ventral hippocampus but cell counts were not performed in this region. Extensive damage was also recorded in the lateral thalamic nucleus (91% cell loss) while the mediodorsal thalamic nucleus was more moderately damaged (56%).
  • the 60 mg/kg dose was also protective in reducing neuronal damage by 65 and 42% in the lateral and mediodorsal nucleus, respectively.
  • the treatment with the test compound afforded neuronal protection compared to DZP only at the highest dose, 60 mg/kg.
  • the total loss of cells and tissue disorganization observed in layers III-IV of the piriform cortex was identical in pilo-DZP rats and pilo-test compound rats and did not allow any counting in any of the groups.
  • the TC60 treatment reduced neuronal damage recorded in the pilo-DZP rats by 41 and 44%, respectively.
  • the ventral entorhinal cortex neuroprotection was induced by TC60 administration in layers III-IV and reached 31% compared to pilo-DZP rats.
  • the entorhinal cortex there was a slight worsening of cell loss in pilo-TC10 rats compared with pilo-DZP rats in layers III-IV of the dorsal entorhinal cortex (28% more damage) and layers III- IV of the ventral entohinal cortex (35% more damage).
  • cell loss in the entorhinal cortex was similar to the one recorded in pilo-DZP rats.
  • Timm staining was present both on the upper and lower blades of the dentate gyrus.
  • results of the present study show that a 7-day treatment with the test compound starting at 1 h after the onset of SE is able to protect some brain areas from neuronal damage, e.g., in the pyramidal cell layer of the CA1 and CA3b area, the mediodorsal thalamus, layers Il and Il MV of the piriform cortex and layers III-IV of the ventral entorhinal cortex, but only at the highest dose the test compound, i.e. 60 mg/kg.
  • the latter dose of the test compound is also able to delay the occurrence of SRS, at least in a subgroup of animals that became epileptic with a mean delay that was about 9-fold longer than in the other groups of animals and one animal did not become epileptic in a delay of 9 months after SE.
  • This acute seizure period is followed by a "silent" seizure-free phase lasting for a mean duration of 14-25 days after which all animals exhibit spontaneous recurrent convulsive seizures at the usual frequency of 2 to 5 per week (See, Turski L, lkonomidou C, Turski WA, Bortolotto ZA, Cavalheiro EA (1989) Review: Cholinergic mechanisms and epileptogenesis, The seizures induced by pilocarpine: a novel experimental model of intractable epilepsy Synapse 3:154-171 ; Cavalheiro EA (1995) The pilocarpine model of epilepsy, ltal J Neurol Sci 16:33-37; Dube C, Boyet S, Marescaux C, Nehlig A (2001) Relationship between neuronal loss and interictal glucose metabolism during the chronic phase of the lithium- pilocarpine model of epilepsy in the immature and adult rat. Exp Neurol 167:227-241)).
  • AED's The current antiepileptic drugs (AED's) do not prevent epileptogenesis and are only transiently efficient on recurrent seizures.
  • TC TC 1 i.e. 30, 60, 90 and 120 mg/kg (TC30, TC60, TC90 and TC120) were tested using the same design as in the previous study.
  • the treatment was started one hour after the onset of SE and the animals were treated with a second injection of the same dose of the drug. This early treatment of SE was followed by a 6 days TC treatment.
  • This report concerns the effects of the four different doses of TC on neuronal damage assessed in hippocampus, parahippocampal cortices, thalamus and amygdala at 14 days after SE and on the latency to and frequency of spontaneous epileptic seizures.
  • the rats surviving SE were then injected about 10 h after the first TC injection with a second i.p. injection of 1.25 mg/kg DZP for the DZP group or of the same dose of TC as in the morning and were maintained under a twice daily TC treatment (s.c.) for 6 additional days while DZP rats received a vehicle injection.
  • the effects of DZP and the 4 doses of TC on epileptogenesis were investigated by daily video recording of the animals for 10 h per day. Video recording was performed for 4 weeks during which the occurrence of the first seizure was noted as well as the total number of seizures over the whole period. Animals were then taken off the video recording system and kept for 4 additional weeks in our animal facilities before they were sacrificed after a total period of 8 weeks of epilepsy. The rats that did not exhibit seizures were sacrificed after 5 months of video recording. Quantification of cell densities
  • Quantification of cell densities was performed at two times after SE: a first group was studied 14 days after SE and was composed by 7 DZP, 8 TC30 , 11 TC60 , 10 TC90 , 8 TC120 and 8 control rats not subjected to SE. A second group used for the study of the latency to SRS was sacrificed either 8 weeks after the first SRS or at 5 months when no SRS could be seen in that delay and was composed of 14 DZP, 8 TC30 , 10 TC60 , 11 TC90 , 9 TC120 rats. At the moment, neuronal counting is still in progress in the second group of animals studied for epileptogenesis and long-term counting and the data concerning that part of the study will not be included in the present report.
  • mice were deeply anesthetized with 1.8 g/kg pentobarbital (Dolethal®, Vetoquinol, Lure, France). Brains were then removed and frozen. Serial 20 ⁇ m slices were cut in a cryostat, air-dried during several days before thionine staining. Quantification of cell densities was performed with a 10 x 10 boxes 1 cm 2 microscopic grid on coronal sections according to the stereotaxic coordinates of the rat brain atlas (Paxinos G, Watson C (1986) The Rat Brain in Stereotaxic Coordinates, 2nd ed. Academic Press, San Diego).
  • the grid of counting was placed on a well defined area of the cerebral structure of interest and counting was carried out with a microscopic enlargement of 200- or 400-fold defined for each single cerebral structure.
  • Cell counts were performed twice on each side of three adjacent sections for each region by a single observer unaware of the animal's treatment. The number of cells obtained in the 12 counted fields in each cerebral structure was averaged. This procedure was used to minimize the potential errors that could result from double counting leading to overestimation of cell numbers. Neurons touching the inferior and right edges of the grid were not counted.
  • Counts involved only neurons with cell bodies larger than 10 ⁇ m. Cells with small cell bodies were considered as glial cells and were not counted. Data analysis
  • Li-pilo lithium-pilocarpine
  • rats developed a full characteristic Li-pilo SE.
  • the behavioral characteristics of SE were identical in both li-pilo-DZP and li-pilo-TC groups.
  • rats developed diarrhea, piloerection and other signs of cholinergic stimulation.
  • rats During the following 15- 20 min, rats exhibited head bobbing, scratching, chewing and exploratory behavior. Recurrent seizures started around 15-20 min after pilocarpine administration.
  • the degree of mortality over the first 48 h after SE was the following: 7% (1/14) of DZP rats, 27% (3/11) of TC30 rats, 0% (0/10) of TC60 rats, 0% (0/11) of TC90 rats and 0% (0/9) of TC120 rats died.
  • DZP rats one rat died during the first 24 h after SE.
  • TC30 two rats were dead by 24 h and one by 48 h after SE.
  • DZP rats Compared to control rats, the number of neurons was massively decreased in the CA1 region of the hippocampus (85% drop out in the pyramidal cell layer) while the CA3 region was less extensively damaged (40% loss) (Table 1 and Figure 1). In the dentate gyrus, DZP rats experienced extensive neuronal loss in the hilus (65%) while the granule cell layer did not show overt damage. The same distribution of damage was observed in the ventral hippocampus but cell counts were not performed in this region.
  • neuronal loss was moderate in the mediodorsal central and lateral, the dorsolateral medial dorsal and in the central medial nuclei (18, 24, 40 and 34% drop out, respectively), more marked in the mediodorsal nucleus (49%) and major in the ventral lateral division of the dorsolateral nucleus (90%) (Table 1 and Figure 2).
  • neuronal loss was moderate in the medial ventral posterior nucleus (38%) and more marked in the basolateral and medial dorsal anterior nuclei (73 and 53% drop out, respectively). There was no neuronal damage in the central nucleus (Table 1 and Figure 3).
  • Table 1 Effects of increasing doses of Test Compound (TC) on the number of neuronal cell bodies in the hippocampus, thalamus, amygdala and cerebral cortex of rats subjected to li-pilo SE.
  • TC was significantly protective at the 60 mg/kg dose in the dorsolateral medial dorsal nucleus and at the two highest doses, 90 and 120 mg/kg in all thalamic nuclei, although the difference did not reach significance in the mediodorsal central and central medial nuclei in TC90 rats.
  • TC120 rats neuronal drop out was considerably reduced compared to DZP rats. It ranged from 4-19% and the number of neurons was no longer significantly different from control animals, except in the dorsolateral medial dorsal nucleus (Table 1 and Figure 2).
  • TC was significantly protective at the 30 mg/kg dose in the basolateral nucleus and at the 60 mg dose, also in the medial dorsal anterior nucleus. At the highest dose, TC was largely neuroprotective; the number of neurons was no longer significantly different from the control level and reached 86-99% of the control level in all amygdala nuclei (Table 1 and Figure 3).
  • the treatment with TC did not significantly protect any cortical area compared to the DZP treatment at the dose of 30 mg/kg.
  • TC significantly reduced neuronal loss only in layer Il of the dorsal piriform cortex (25% drop out compared to 66% in the DZP group).
  • TC significantly protected all three areas of the piriform cortex compared to the DZP treatment and at the highest dose of TC, 120 mg/kg, neuronal density reached 78-96% of control levels, even in piriform cortex, dorsal layer Il and layer III where the neuronal population was almost totally depleted in the DZP group.
  • the latency to spontaneous seizures reached a mean value of 15.5 ⁇ 2.3 days in the DZP group (14 rats) and was similar (11.6 ⁇ 2.5 days) in the TC30 group (8 rats).
  • animals could be subdivided in subgroups with short and long latencies.
  • a short latency was considered as any duration shorter than 40 days after SE.
  • Some rats exhibited a latency to the first spontaneous seizure that was similar to that recorded in the DZP and TC groups but the number of rats exhibiting this short latency values progressively decreased with the increase in TC concentration.
  • 70% of the rats (7/10) had short latencies to seizures while at 90 and 120 mg/kg, this percentage reached 36% (4/11) and 11% (1/9), respectively (Table 2 below and Figure 5).
  • Table 2 Effect of increasing doses of TC on the latency to spontaneous seizures.
  • TC protects also thalamus and amygdala nuclei.
  • TC is not protective at the dose of 30 mg/kg, except in CA1 , one thalamic and one amygdala nucleus.
  • layer Il of the dorsal piriform cortex and a second amygdala nucleus are also protected.
  • the drug protects most cerebral regions studied, except hippocampal CA3 and the hilus of the dentate gyrus.
  • the latter two structures plus the dorsolateral ventral dorsal thalamic nucleus are the only regions where the number of neurons remains significantly different from controls at the dose of 120 mg/kg TC. From these data, the extremely powerful neuroprotection properties of TC appear clearly.
  • the molecule seems to prevent neuronal death in most regions belonging to the circuit of limbic epilepsy induced by Li-pilo, i.e., the hippocampus, thalamus, amygdala and parahippocampal cortices.
  • the treatment did not affect the latency to the first spontaneous seizure at the dose of 30 mg/kg.
  • a percentage of animals developed epilepsy as fast as the DZP or TC30 rats but the relative importance of this subgroup was inversely related to the dose of TC used.
  • Another subgroup, constant in size (2-4 animals per group) developed epilepsy after a 4-6 times longer latency while at the two highest doses of the drug, 4-5 rats had not become epileptic after 5 months, i.e. about 10 times the duration of the short latency and 2-3 times that of the long latency. This delay in the occurrence of epilepsy might correlate with the number of neurons protected in the basal cortices in the animals.
  • the data obtained in the present study are in line with the previous study from this group reporting that the 60-mg/kg dose of Test compound (TC) protected the hippocampus and the basal cortices from neuronal damage and delayed the occurrence of recurrent seizures (see Example 1). They confirm that the protection of the basal cortices could be a key factor in inducing a disease modifying effect in the lithium-pilocarpine model of epilepsy.
  • TC Test compound
  • Andre V Marescaux C, Nehlig A, Fritschy JM (2001) Alterations of the hippocampal GABAergic system contribute to the development of spontaneous recurrent seizures in the lithium-pilocarpine model of temporal lobe epilepsy. Hippocampus 11 :452-468. ⁇ Andre V, Rigoulot MA, Koning E, Ferrandon A, Nehlig A (2003) Long-term pregabalin treatment protects basal cortices and delays the occurrence of spontaneous seizures in the lithium-pilocarpine model in the rat. Epilepsia 44:893-903. ⁇ Cavalheiro EA (1995) The pilocarpine model of epilepsy, ltal J Neurol Sci 16:33-37.
  • Serum withdrawal is a cytotoxic environmental challenge that results in cell death in cultured cell lines as well as in primary cells of various tissue origins, including nerve cells.
  • pheochromocytoma (PC) 12 cells have been widely employed as an in vitro neuronal cell model for a wide variety of neurodegenerative and cell death related disorders (Muriel, et al, Mitochondrial free calcium levels (Rhod-2 fluorescence) and ultrastructural alterations in neuronaily differentiated PC12 cells during ceramide-dependent cell death, J. Comp.
  • the culture medium also contained Penicillin- Streptomycin-Neomycin antibiotic (50 .mu.g, 50 .mu.g, 100 .mu.g, respectively). Medium was exchanged every other day and the cells were passed in log phase near confluence.
  • the control cells were cultured in regular media without any treatment.
  • An enantiomer of Formula 7 or Formula 8 (10 .mu.M) was mixed well in the medium and then applied to the cells.
  • an enantiomer of Formula 7 or Formula 8 (10 .mu.M) was only applied to the cells once at the time of serum withdrawal.
  • an enantiomer of Formula 7or Formula 8 (10. mu.M) was applied to the cells at the time of serum withdrawal and every 48 hr thereafter when cells were changed with fresh new serum-free medium.
  • the cells were cultured in serum-free medium with no additional enantiomer of Formula 7 or Formula 8.
  • Cell survival was determined by the 3-(4, 5-dimethylthiazo!-2-yl)-5-(3-carboxy- - methoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium inner salt (MTS) assay at 2 or 7 days after serum withdrawal.
  • MTS assay is a calorimetric method for determining the number of viable cells in a given experimental setting. The assay is based on the cellular conversion of the tetrazolium salt, MTS, into a formazan that is soluble in tissue culture medium and measured directly at 490 nm in 96-well assay plates. The absorbance is directly proportional to the number of living cells in culture. The arbitrary absorbance reading in control cells is expressed as 100% survival rate.
  • Table 3 lists data demonstrating the effect on cell survival rate of the orally administered enantiomer of Formula 7 and Formula 8 in the PC12 cell serum withdrawal model.
  • the enantiomer of Formula 7 was investigated in the transient cerebral ischemia middle cerebral artery occlusion (MCAO) rat model (as described in Nagasawa H. and Kogure K., Stroke, 1989, 20, 1037; and, Zea Longa E., Weinstein P. R., Carlson S. and Cummins R., Stroke, 1989, 20, 84) using male Wistar rats at 10 and 100 mg/kg (i.v.).
  • MK 801 Dizocilpine maleate; CAS Registry number 77086-22-7, a commercially available neuroprotectant compound
  • One hour after blockage animals were treated over a 1 hour period with vehicle (administered i.v. over the one hour period), control (administered as a single i.p. dose at the start of the one hour period) and two doses of the enantiomer of Formula 7 (administered i.v. over the one hour period).
  • Two hours after blockage reperfusion was performed. The animals were sacrificed and 20 mm-thick coronal sections of each brain were prepared. One in every forty sections (i.e.
  • the mean volumes (.+-.S. E. M.) for each animal randomly assigned to the four experimental groups were compared using one-way ANOVA (one way ANOVA is a statistical method which compares 3 or more unmatched groups) followed by Dunnett's t-test (both methods incorporated in Statview 512+software, BarinPower, Calabasas, Calif., USA).
  • results were considered statistically significant when the p value was ⁇ 0.05 compared to vehicle group ( 1 p ⁇ 0.01 ; 2 p ⁇ 0.05).
  • Test Compound (TC) referred to in the example below is the compound of Formula 7 and the same compound as in the other examples 1 and 2 above.
  • the purpose of this study was to assess the pharmacokinetics (PK) of
  • Test Compound (TC) following single and repeated oral administration in healthy adult men at clinically relevant doses RESULTS:
  • study 1 Two single-center, placebo-controlled, double-blind, ascending-dose studies were conducted in healthy men >18 and ⁇ 45 yrs.
  • study 1 subjects were randomly assigned to a single dose of Test Compound (TC) or placebo.
  • Escalated doses were received as 100, 250, 400, 750, 1000, 1250, and 1500 mg.
  • PK parameters were estimated from plasma and urine samples collected up to 3 days post dose.
  • PK parameters were estimated from plasma and urine samples on days 1 and 7.
  • Repeated doses Plasma concentrations of Test Compound (TC) reached steady state after 3-4 days as predicted from its single-dose half-life. Mean t max occurred 1.3-1.8 h after dosing.
  • Test Compound (TC) exhibited linear PK after single (100-1500mg) and repeated (100-750 mg bid) doses. It was rapidly absorbed and had a mean elimination half life of 11.5-13.9 h, allowing bid dosing. Following q12h administration, Test Compound (TC) accumulated two-fold and was primarily cleared by a non-renal pathway.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)

Abstract

La présente invention concerne des procédés permettant de fournir une neuroprotection qui consiste à administrer un sujet nécessitant un traitement une quantité thérapeutiquement efficace d'un composé sélectionné dans le groupe représenté pat les formules (I) et (II), ou un sel ou un ester de ce composé répondant aux normes pharmaceutiques. Dans ces formules, phényle est substitué à X avec un à 5 atomes halogène sélectionnés dans le groupe constitué de fluor, chlore, brome et iode et R1, R2, R3, R4, R5 et R6 sont sélectionnés indépendamment dans le groupe constitué de l'hydrogène et de C1-C4 alkyle; C1-C4 alkyle étant éventuellement substitué avec phényle (phényle étant éventuellement substitué avec des substituants indépendamment sélectionné dans le groupe constitué de halogène, C1-C4 alkyle, C1 C4 alcoxy, amino, nitro et cyano).
EP05810159A 2004-10-15 2005-10-14 Composes carbamate destines au traitement de pathologies neurodegeneratives Withdrawn EP1802294A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61940204P 2004-10-15 2004-10-15
US69840305P 2005-07-12 2005-07-12
PCT/US2005/036695 WO2006044472A1 (fr) 2004-10-15 2005-10-14 Composes carbamate destines au traitement de pathologies neurodegeneratives

Publications (1)

Publication Number Publication Date
EP1802294A1 true EP1802294A1 (fr) 2007-07-04

Family

ID=35840528

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05810159A Withdrawn EP1802294A1 (fr) 2004-10-15 2005-10-14 Composes carbamate destines au traitement de pathologies neurodegeneratives

Country Status (14)

Country Link
EP (1) EP1802294A1 (fr)
JP (1) JP2008516961A (fr)
KR (3) KR20090130175A (fr)
AU (1) AU2005295787A1 (fr)
BR (1) BRPI0516112A (fr)
CA (1) CA2584854A1 (fr)
EA (1) EA200700871A1 (fr)
EC (1) ECSP077395A (fr)
IL (1) IL182432A0 (fr)
MX (1) MX2007004491A (fr)
NI (1) NI200700094A (fr)
NO (1) NO20072444L (fr)
SG (1) SG142306A1 (fr)
WO (1) WO2006044472A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011071995A2 (fr) 2009-12-08 2011-06-16 Case Western Reserve University Composés et procédés de traitement de troubles oculaires
US8609849B1 (en) 2010-11-30 2013-12-17 Fox Chase Chemical Diversity Center, Inc. Hydroxylated sulfamides exhibiting neuroprotective action and their method of use
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
KR20190081385A (ko) 2017-12-29 2019-07-09 강원대학교산학협력단 옥스카바제핀을 유효성분으로 함유하는 허혈성 뇌혈관 질환 예방용 조성물
WO2022045824A1 (fr) * 2020-08-31 2022-03-03 Bio-Pharm Solutions Co., Ltd. Composés carbamate de phényle alkyle destinés à être utilisés dans la prévention ou le traitement d'une maladie neurodégénérative
BR112023004354A2 (pt) 2020-09-10 2023-04-04 Bio Pharm Solutions Co Ltd Compostos derivados de sulfamato para uso no tratamento ou alívio de um transtorno psiquiátrico

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010034365A1 (en) * 1996-01-16 2001-10-25 Choi Yong Moon Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol
US5698588A (en) * 1996-01-16 1997-12-16 Yukong Limited Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol
ES2234651T3 (es) * 1999-08-20 2005-07-01 Ortho-Mcneil Pharmaceutical, Inc. Composicion que comprende una materia de tramadol y un farmaco anticonvulsivo.
MXPA03007718A (es) * 2001-02-27 2004-11-12 Johnson & Johnson Compuestos de carbamato para usarse en la prevencion o tratamiento de trastornos neurodegenerativos.
PT1809273E (pt) * 2004-09-16 2010-05-10 Janssen Pharmaceutica Nv Utililização de 2-fenil-1,2-etanodiol-(di)carbamatos para tratamento de epileptogénese

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2006044472A1 *

Also Published As

Publication number Publication date
NO20072444L (no) 2007-06-14
CA2584854A1 (fr) 2006-04-27
EA200700871A1 (ru) 2007-10-26
KR20090130175A (ko) 2009-12-18
JP2008516961A (ja) 2008-05-22
MX2007004491A (es) 2007-08-08
IL182432A0 (en) 2007-09-20
NI200700094A (es) 2008-02-11
AU2005295787A1 (en) 2006-04-27
KR20110049901A (ko) 2011-05-12
ECSP077395A (es) 2007-05-30
WO2006044472A1 (fr) 2006-04-27
KR20070085309A (ko) 2007-08-27
BRPI0516112A (pt) 2008-08-26
SG142306A1 (en) 2008-05-28

Similar Documents

Publication Publication Date Title
US20090137652A1 (en) Methods for neuroprotection
AU2005287174B2 (en) Use of 2-phenyl-1, 2-ethanediol- (di) carbamates for treating epileptogenesis and epilepsy
US20070021501A1 (en) Methods of treating epileptogenesis
WO2006044472A1 (fr) Composes carbamate destines au traitement de pathologies neurodegeneratives
CA2439295C (fr) Composes a base de carbamate destines a etre utilises dans la prevention ou le traitement de troubles neurodegeneratifs
US20080103198A1 (en) Methods for treatment of cochlear and vestibular disorders
EP1809273B1 (fr) Utilisation de 2-phenyl-1,2-ethanediol-(di)carbamates pour le traitement de l'epileptogenese

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070419

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK YU

17Q First examination report despatched

Effective date: 20090907

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20120501